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Chronic obstructive pulmonary disease (COPD) has a profound impact on daily life, yet remains underdiagnosed and undertreated. 
This study aims to discover potential protein biomarkers for diagnosis and classification of COPD. Fifty-seven COPD patients and 
40 controls were divided into a training set (30 COPD patients, 20 healthy controls) and a test set (27 COPD patients, 20 healthy 
controls). Serum proteomic profiles were measured using surface-enhanced laser desorption/ionization time-of-flight mass spec-
trometry (SELDI-TOF-MS). A classification tree was established using Biomarker Pattern Software (BPS). Next we screened 
distinct proteins present in patients with acute exacerbations of COPD (AECOPD), stable COPD and healthy controls, in order to 
establish diagnostic models for classification of COPD. Twenty peaks showed statistically significant differences between COPD 
patients and healthy controls (P < 0.05). Two proteomic peaks (3167 and 5477 m/z) were chosen by BPS to establish a classifica-
tion tree in the training set. The sensitivity and specificity of this classification tree were 92.59% and 90.00% respectively in the 
testing set. Furthermore, differently expressed proteins were detected among the patients with AECOPD, stable COPD, and 
healthy controls. Two protein profiles (3167 and 4645 m/z) could distinguish between stable COPD patients and healthy controls. 
Three protein profiles (3167, 2963 and 2973 m/z) could distinguish between AECOPD patients and healthy controls. Three pro-
tein profiles (5476, 14039 and 2831 m/z) could distinguish between stable COPD patients and AECOPD patients. SELDI-TOF- 
MS Proteinchip technology is a quick, easy and practical, high throughput analytic method. It shows the diagnostic models estab-
lished by distinguished proteomic peaks can discriminate COPD patients from healthy control and can identify different stages of 
COPD. It will provide a highly accurate approach for diagnosis and clinical staging of COPD. 
chronic obstructive pulmonary disease, surface-enhanced laser desorption/ionization time-of-flight mass spectrometry, 
proteomics 
 




Chronic Obstructive Pulmonary Disease (COPD) is recog-
nized as a major public health problem with increasing 
morbidity and mortality [1]. It has been forecasted that 
COPD will be ranked third as a cause of mortality by 2020, 
and the prevalence of COPD is most often reported in the 
range of 6%–10% of the total adult population [2,3]. COPD 
is characterised by airflow limitation that is progressive and 
not fully reversible [4]. The onset of COPD is generally 
insidious, with slowly evolving symptoms, and the percep-
tion of these symptoms as ‘self-inflicted’ by patients and 
physicians may lead to significant delay in medical consul-
tation and initiation of therapy [5,6]. Early diagnosis of this 
disease is a challenge for the coming years [7]. Repeated 
acute exacerbation COPD (AECOPD) is a major public 
health problem. They are important clinical events and have 
prognostic signifcance [8], so study of AECOPD is one of 
the practical problems we need to face. At present, diagnos-
tic criteria for AECOPD has not yet been standardized, and 
there is no uniform diagnostic criteria to distinguish be-
tween stable COPD and AECOPD in China. In the tradi-
tional way, classification is based on clinical features. To 
date, no specific biological markers have been used to iden-
tify this disease. 
Recent advances in proteomic analysis have offered ex-
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citing opportunities for finding novel biomarkers in biolog-
ical fluids, especially in sera [9–13]. Surface-assisted laser 
desorption/ionization time-of-flight mass spectrometry 
(SELDI-TOF-MS) offers a rapid and robust approach for 
protein biomarker discovery without the need for purifica-
tion and separation of proteins prior to analysis [14,15]. It 
has proved to be a powerful tool for potential biomarker 
discovery [16–22]. Findings from previous studies suggest 
that SELDI-TOF-MS may facilitate detection of COPD- 
associated serum biomarkers [23]. However, larger cohorts 
will be needed to validate these biomarkers and determine 
their predictive value in longitudinal studies. And to date, 
there are no published reports evaluating the efficacy of 
SELDI-TOF-MS for distinguishing stable COPD patients 
from AECOPD patients. 
In this study, we first used SELDI-TOF-MS technology 
to screen potential protein patterns specific to COPD, and 
next, to screen distinct proteins in different stages of COPD 
in order to establish diagnostic models for clinical staging 
of COPD. 
1  Materials and methods  
1.1  Sample collection 
Serum samples were collected from the Department of Res-
piratory Diseases at Beijing Tiantan Hospital, Capital Med-
ical University, China. Patients with COPD were diagnosed 
according to the Global Initiative for Obstructive Lung 
Disease (GOLD) criteria. This study included 97 specimens, 
57 samples of which were obtained from COPD patients 
and 40 samples which were obtained from healthy controls 
in the medical center of Beijing Tiantan Hospital during 
routine examinations (Table 1). COPD patients (baseline 
FEV1, (49.6 ± 17.2)% of predicted) fulfilled GOLD criteria 
with FEV1/FVC < 70%. Healthy controls were without 
pulmonary disease and FEV1/FVC > 80%. COPD patients 
were separated into stable COPD patients and AECOPD 
patients, according to GOLD criteria. We obtained informed 
consent from all subjects and approval from the Beijing 
Tiantan Hospital ethical committee. 
The specimens were separated into two groups: (1) the 
training group, with 30 COPD patients (15 stable COPD 
patients, 15 AECOPD patients) and 20 healthy controls, was 
used to establish the diagnosis model (Model I) to distin-
guish between COPD patients and healthy controls. (2) The 
testing group, with 27 COPD patients (15 stable COPD pa-
tients, 12 AECOPD patients) and 20 healthy controls, was 
analyzed to validate the accuracy and validity of the diag-
nosis model (Model I) derived from the training group. 
Thirty cases of stable COPD patients and 30 healthy 
controls (30 cases of healthy controls were selected from 
the 40 cases of healthy controls, and age and sex-matched to 
the stable COPD patients) were used to establish the diag-
nosis model (Model II) to distinguish between stable COPD  
Table 1  Characteristics of COPD patients and healthy controls 
Characteristics Number 
COPD patients 
   Mean age (age range)  
   Sex  
Male  
Female 
   Stage 
      Stable COPD patients 
      AECOPD patients 
   Stable COPD patients 
      Mean age (age range)  
      Sex  
Male  
Female 
   AECOPD patients 
      Mean age (age range)  




   Mean age (age range)  



























patients and healthy controls. Twenty-seven cases of 
AECOPD patients and 27 healthy controls (27 cases of 
healthy controls were selected from the 40 cases of healthy 
controls, and age and sex-matched with AECOPD patients) 
were used to establish the diagnosis model (Model III) to 
distinguish between stable AECOPD patients and healthy 
controls; 15 cases of stable COPD patients and 15 cases of 
AECOPD patients (15 cases of stable COPD patients were 
selected from the 30 cases of stable COPD patients, and 15 
cases of AECOPD patients were selected from the 30 cases 
of AECOPD patients and age and sex-matched with stable 
COPD patients) were used to establish the diagnosis model 
(Model IV) to distinguish between stable COPD patients 
and AECOPD patients. 
All blood samples were collected in the morning before 
breakfast. They were stored at 4°C for 2 h and then centri-
fuged at 3500 r/min for 5 min. All serum samples were 
stored at −80°C for further analysis. 
1.2  SELDI protein profiling  
Serum samples were thawed on ice and centrifuged at 
10000 r/min for 2 min. A total of 20 µL of U9 buffer     
(9 mol/L urea, 2% CHAPS, 2 mmol/L DTT and 50 mmol/L 
Tris-HCl, pH 9) (Sigma, Santa Clara, USA) were added to 
10 µL of each serum sample, and the solutions were vor-
texed for 30 min. The resulting serum solutions were further 
diluted by 360 µL of buffer solution (50 mmol/L sodium 
acetate, pH 4.0) (Sigma). Weak Cation Exchange protein 
chips, CM10 (Ciphergen Biosystems, Fremont, USA) were 
pre-equilibrated with 200 µL of buffer solution twice. Next, 
100 µL of diluted serum sample was added to each spot of 
the CM10 protein chip in a bioprocessor (Ciphergen Bio-
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systems). The bioprocessor was then sealed and agitated on 
a platform shaker for 60 min at 4°C. After discarding the 
remaining samples, the chips were washed with 200 µL of 
buffer solution for 5 min. This procedure was repeated 
twice, with a brief water rinse after application of buffer 
solution. The chips were then removed from the bioproces-
sor and air-dried. Each spot on the chip received two appli-
cations of 0.5 µL of a saturated sinapinic acid in 50% (v/v) 
acetontrile and 0.5% (v/v) trifluoroacetic acid (Sigma), and 
the chips were air-dried. ProteinChip Arrays were read by 
surface-enhanced laser desorption/ionization time-of-flight 
mass spectrometry (Ciphergen Biosystems). The optimal 
detection parameter of mass/charge size range was set be-
tween 2000 and 20000 m/z with a maximum of 50000 m/z. 
The laser intensity was set at 150 and detector sensitivity 
was set at 8. The all-in-one peptide molecular mass standard 
(Ciphergen Biosystems) was used to generate a peptide 
standard spectrum for mass accuracy calibration. 
1.3  Bioinformatics and biostatistics 
Details of classification and regression tree analysis have 
been previously described [24]. The SELDI-TOF-MS were 
obtained and analyzed using Ciphergen Protein Chip Soft-
ware 3.1.1. Peak labeling was performed by the Biomarker 
Wizard Software. The P value for statistical significance 
was set at 0.05. The intensities of selected peaks were sub-
sequently transferred to BPS to construct the classification 
tree of all.  
2  Results 
2.1  Comparison of serum protein spectra between 
COPD patients and healthy controls in the training set 
Serum samples from the training set were evaluated by 
comparing the results obtained by SELDI-TOF-MS with 
those from the CM10 chip. Twenty peaks showed statisti-
cally significant differences between COPD patients and 
healthy controls (P < 0.05) (Table 2). Among them, 8 pro-
tein peaks (3270, 3514, 9315, 9369, 9430, 11501, 11545 
and 11717 m/z) were up-regulated and 12 protein peaks 
(2086, 2880, 2944, 2973, 3167, 3215, 3937, 4093, 4176, 
5439, 5477 and 5921 m/z) were down-regulated in serum 
samples from patients with COPD. Figure 1 shows one pro-
tein peak (3167 m/z) was down-regulated in COPD patients. 
2.2  Decision tree classification (Model I) 
To set up a classification tree as a diagnostic model, the 
intensities of protein peaks in the training set were trans-
ferred to BPS. A total of two peaks (3167 and 5477 m/z) 
were automatically selected to construct a classification tree 
(Figure 2). All 50 cases in the training set entered the classi-
fication tree from the root node in the first layer, which     
Table 2  The average peak intensity of 19 distinct protein spectra found in 
sera of COPD patients and healthy controls (P <0.05) 
m/z P COPD Controls 
3167 4.60×10–9 3.58±1.9 11.13±4.37 
5477 1.00×10–6 3.77±3.15 9.64±2.47 
3937 1.82×10–6 11.12±5.13 23.40±8.50 
4176 1.58×10–6 3.37±1.30 6.91±3.24 
11717 2.30×10–4 1.96±2.28 0.55±0.23 
11545 9.42×10–4 1.02±1.10 0.35±0.16 
2944 1.16×10–3 4.56±1.70 7.98±4.86 
2880 2.97×10–3 5.75±3.89 8.89±3.74 
11501 8.44×10–3 1.03±1.35 0.34±0.14 
3514 0.015 2.64±2.87 0.83±1.40 
9369 0.018 5.22±4.15 2.46±1.20 
4093 0.029 51.32±10.54 59.56±13.31 
3215 0.030 2.32±2.03 4.32±4.02 
2973 0.034 3.91±2.53 5.43±2.58 
9315 0.037 6.57±2.99 4.74±1.64 
3270 0.039 6.27±3.28 5.05±4.58 
5921 0.043 20.37±9.18 25.54±9.30 
5349 0.045 2.30±2.26 4.22±3.65 
2086 0.049 6.75±3.48 8.50±3.12 
9430 0.050 5.94±4.13 3.45±1.85 
 
splited into two nodes in the second layer, according to the 
peak intensity with a m/z value of 3167 m/z. Twenty-eight 
cases were assigned to terminal node 1, because their peak 
intensity value was ≤5.982, while 22 cases were assigned to 
node 2, because their peak intensity value was >5.982. In 
the third layer, the 22 cases in node 2 were classified into 
terminal node 2 (COPD patients) and terminal node 3 
(healthy controls) according to the peak intensity with a m/z 
value of 5477 m/z. The classification tree using the combi-
nation of these two protein peaks identified 30 COPD pa-
tients and 20 healthy controls, resulting in a sensitivity of 
100% (30/30), a specificity of 100% (20/20) and an accura-
cy rate of 100% (50/50) respectively (Table 3).  
2.3  Decision tree classification (Model I) validation  
To validate the accuracy of the classification model derived 
from the training set, we applied the derived classification 
tree to a test data set consisting of samples from 27 COPD 
patients and 20 healthy controls. The classification tree dis-
criminated the COPD samples from the controls with a sen-
sitivity of 92.59% (25/27), a specificity of 90.00% (18/20), 
and a accuracy rate of 91.49% (43/47) (Tables 3). The area 
under the receiver operating characteristics (ROC) curve of 
this model was 0.913 (Figure 3). 
2.4  Decision tree classification (Model II) 
Nineteen peaks showed statistically significant differences 
between the 30 stable COPD patients and 30 healthy controls 
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Figure 1  Detection of protein of mass pattern in sera. Mass spectra of serum samples from two COPD patients and two health controls. One protein peak (3167 
m/z) was down-regulated in COPD patients. 3167 m/z was a median calculated by Biomarker Wizard Software, and the floating range was less than 0.3%. 
Table 3  Performance of of the classification tree analysis ( Model I ) in the training and testing sets 
Sets Groups Sensitivity (%) Specificity (%) Accuracy rate (%) 
Training set 30 COPD/ 20 controls 100 100 100 




Figure 2  Classification of COPD patients (red) and healthy controls 
(blue) in the training set.  
 
 
Figure 3  The area under ROC curve of Model I. 
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(P < 0.05). Among them, four protein peaks (2069, 9367, 
9434 and 11510 m/z) were up-regulated and 15 protein 
peaks (2702, 2880, 2944, 3167, 3936, 4176, 4297, 4474, 
4645, 5299, 5380, 5477, 7777, 7986 and 14775 m/z) were 
down-regulated in serum samples from patients with stable 
COPD. Two peaks (3167 and 4645 m/z) were automatically 
selected to construct a classification tree that could signifi-
cantly distinguish between stable COPD patients and con-
trols. The classification tree using the combination of these 
two protein peaks identified 30 stable COPD patients and 
30 healthy controls, resulting in a sensitivity of 96.67% 
(29/30) and a specificity of 96.67% (29/30) (Table 4).  
2.5  Decision tree classification (Model III) 
Twenty-four peaks showed statistically significant differ-
ences between 27 AECOPD patients and 27 healthy controls 
(P < 0.05). Among them, 13 protein peaks (2963, 3271,  
3514, 5802, 5836, 6115, 9312, 9371, 9434, 9731, 11445, 
11519 and 11730 m/z) were up-regulated and 11 protein 
peaks (2558, 2880, 2944, 2973, 3167, 3937, 4283, 4297, 
4649, 5477 and 14049 m/z) were down-regulated in serum 
samples of patients with AECOPD. Three peaks (3167, 
2963 and 2973 m/z) were automatically selected to construct 
a classification tree that could significantly distinguish be-
tween AECOPD and controls. The classification tree using 
the combination of these three protein peaks identified 27 
stable COPD patients and 27 healthy controls, resulting in a 
sensitivity of 100% (27/27) and a specificity of 100% 
(27/27) (Table 4).  
2.6  Decision tree classification (Model IV) 
Eight peaks showed statistically significant differences be-
tween 15 stable COPD patients and 15 AECOPD patients 
(P < 0.05). They (2831, 3936, 5335, 5476, 7776, 7982, 9312 
and 14039 m/z) were all up-regulated in serum samples of 
patients with AECOPD. Three peaks (5476, 14039 and 
2831 m/z) automatically selected to construct a classifica-
tion tree could significantly distinguish between stable 
COPD and AECOPD. The classification tree using the 
combination of these three protein peaks identified 15 stable 
COPD patients and 15 AECOPD patients, resulting in a 
sensitivity of 93.33% and a specificity of 100% respectively 
(Table 4). One in 15 stable COPD samples was misclassi-
fied. 
2.7  Comparison of serum protein spectra between sta-
ble COPD, AECOPD patients and healthy controls 
Nineteen peaks showed statistically significant differences 
between stable COPD, AECOPD patients and healthy con-
trols (P < 0.05). Among them, intensities of proteins with 
5802, 5839, 9371, 9731 and 11445 m/z were orderly in-
creasing from healthy controls, stable COPD to AECOPD. 
Intensity of protein with m/z 2303 was orderly reducing 
from healthy controls, stable COPD to AECOPD. Intensi-
ties of proteins with 2880, 3167, 3936, 4140, 4297, 4645, 
5478, 5921 and 6451 m/z were orderly reducing from 
healthy controls, AECOPD to stable COPD.   
3  Discussion 
In this study, we obtained serum protein mass spectra from 
COPD patients and healthy controls using SELDI-TOF-MS. 
Twenty peaks had statistically significant differences be-
tween 30 COPD patients and 20 healthy controls (the train-
ing set. Among them, eight protein peaks were up-regulated 
and 12 were down-regulated in serum samples of patients 
with COPD). Up-regulated proteins may be those which 
promote the occurrence and development of COPD; 
down-regulated proteins may be those conducive to the 
maintenance of lung structure and function. Identification of 
these proteins will help understand the pathogenesis of 
COPD. We used a two-step approach for proteomic bi-
omarker screening. To translate from proteomic peaks to 
proteomic signatures for discriminating COPD patients 
from healthy controls, we utilized BPS to select the best 
proteomic peaks for construction of classification tree [25]. 
The classification tree using the combination of the two 
peaks (3167 and 5477 m/z) identified 30 COPD and 20 
healthy subjects with a calculated sensitivity of 100% and a 
specificity of 100%. To validate the accuracy and validity of 
the classification model derived from the training set, we 
applied the derived classification tree to a test dataset con-
sisting of 27 COPD and 20 control samples. The classifica-
tion tree discriminated the COPD samples from the controls 
with a sensitivity of 92.59% and a specificity of 90.00%. So 
we consider that SELDI-TOF-MS technology can detect 
several specific markers from COPD sera that have clinical 
significance in the diagnosis of COPD. The two proteins 
selected using this technique (3167, 5477 m/z) may play an 
important role in the pathogenesis of COPD.   
Table 4  Performance of the classification tree analysis (models II–IV)  
Models Groups Sensitivity (%) Specificity (%) Accuracy rate (%) 
Model II 30 Stable COPD/30 controls     96.67 96.67         96.67 
Model III 27 AECOPD/27 controls 100 100           100 
Model IV    15 COPD/15 AECOPD 93.33 100           96.67 
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Currently, in literature, few SELDI-TOF-MS studies on 
COPD are reported, especially performed on serum samples. 
Bowler et al. [23] identified a panel of five biomarkers us-
ing the IMAC protein chip that could distinguish COPD 
patients from controls with sensitivity and specificity of 
91.67% and 88.33%. Our and Bowler’s studies have 
demonstrated the feasibility of using SELDI as a diagnostic 
test for COPD, and that the serum protein fingerprint of 
COPD patients is different from that of healthy people. This 
permits to reveal low abundance proteins in serum and 
plasma samples, as needed for biomarker discovery [26–28]. 
However, our research results differ from those of Bowler’s 
study. Different experimental conditions, a different chip 
choice, different study selection criteria, as well as ethnic, 
regional and other factors could explain the difference in 
results.  
In order to search for COPD-related protein in phases, we 
compared the proteomic spectra of stable COPD patients, 
AECOPD patients and healthy controls. The study found 
that two protein peaks (3167 and 4645 m/z) could distinguish 
stable COPD patients and healthy controls. Sensitivity and 
specificity were 96.67% and 96.67%. Three protein peaks 
(3167, 2963 and 2973 m/z) could distinguish between 
AECOPD patients and healthy controls, with a sensitivity 
and specificity of 100% and 100%. Three protein peaks 
(5476, 14039 and 2831 m/z) could distinguish between 
stable COPD patients and AECOPD patients, with a sensi-
tivity and specificity of 93.33% and 100%, respectively. 
This shows that the diagnostic models established using 
distinctive proteomic peaks can discriminate between the 
different stages of COPD. Therefore, SELDI-TOF-MS 
technology will not only help the clinical diagnosis of 
COPD, but also the diagnosis of disease stages. By analyz-
ing the models I, II, and III, we find that one protein peak 
(3167 m/z) of the three models was chosen as the root node. 
It may be a marker protein of COPD, and its identification 
and validation may be very important in COPD diagnosis 
and prevention. In addition, serum protein spectra was 
compared between stable COPD, AECOPD patients and 
healthy controls. Five protein peaks (5802, 5839, 9371, 
9731 and 11445 m/z) were found to be orderly increasing 
from healthy controls, stable COPD to AECOPD, and one 
protein peak (2303 m/z) was found to be orderly reducing 
from healthy controls, stable COPD to AECOPD. These 
obvious differentially expressed proteins may have a close 
relationship with the genesis and development of COPD and 
worthy of further study.      
4  Conclusions 
SELDI-TOF-MS protein chip technology is a quick, easy 
and practical, high throughput analytic method. It can detect 
biological markers in COPD, and it shows that the diagnos-
tic models established by distinctive proteomic peaks can 
discriminate COPD patients from healthy control and can 
identify different stages of COPD. It will provide a highly 
accurate approach for diagnosis and clinical staging of 
COPD. However, the present study is a preliminary research, 
further studies, increasing the sample size and including 
other airway obstructive diseases such as asthma into con-
trol group, are needed to confirm these results and especial-
ly to identify and subsequently validate the discovered pro-
tein peaks. In addition, samples from airway locality such as 
sputum can provide information about both inflammatory 
cells and mediators present in the airways [29,30]. Sputum 
reflects the microenvironment of the lung whereas serum 
reflects a processed proteome; combining data on these 
samples may provide the necessary means to understand, 
diagnose and treat COPD [31]. Therefore, in the further 
study, it is meaningful to include sputum proteomics. 
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